Cadila Healthcare Limited has received final approval from the US FDA to market Tizanidine hydrochloride capsules, USP in strengths of 2mg, 4mg and 6mg. The drug, which is a muscle relaxant, will be produced at the SEZ facility located at Ahmedabad. The estimated sales for Tizanidine hydrochloride capsules is $ 58.6 million as per IMS January 2017.
The group now has nearly 110 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.